#KairosPharma's CEO, John Yu, is rethinking how to tackle cancer drug resistance & advance innovative #immunotherapies. In a recent feature with Drug and Device World, he shares insights on $KAPA's approach and pipeline in #cancerresearch Read more: bit.ly/3I0rsNc

In a new A Further Inquiry interview, $KAPA CEO John Yu explains how #ENV105 targets CD105 to help reverse drug resistance in advanced #prostatecancer. ENV105 showed a 13.7-month median PFS in interim Phase 2 data & may suppress AR V7. Read more: bit.ly/4oyGaKC #mCRPC

$KAPA highlights the need for continued innovation in #menshealth and #prostatecancer. Interim findings from our Phase 2 #ENV105 study show encouraging clinical benefit and durable progression-free survival. Learn more: kairospharma.com

#ICYMI: In a Q&A with invezz.com, $KAPA's CEO John Yu shared #Kairos's vision for #ENV105, its potential role in advancing #immunotherapy, and how future partnerships could help scale the company’s impact. Catch up on the full Q&A: bit.ly/41FDsdy #LeadershipInsights

Today, we’re spotlighting $KAPA's Board of Directors, including John Yu, Rahul Singhvi, Hyun Bae, and Michael Keyoung. Their leadership guides #KAPA in advancing next-generation cancer #immunotherapies. Learn more: bit.ly/4pTPI3R #BoardOfDirectors #Leadership

#KairosPharma's CSO, Neil Bhowmick, joined the Citeline In Vivo Podcast to discuss #ENV105 and resensitization therapy in hormone-resistant #prostatecancer, including encouraging Phase 2 data. Listen to the full episode: bit.ly/48yIsoo #KAPA $KAPA #DrugResistance

$KAPA has been named a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced #prostatecancer. The award recognizes progress advancing ENV-105, a first-in-class resistance-modulating antibody. PR: bit.ly/4j3uoH0

Happy Holidays from all of us at #KairosPharma! Wishing everyone a happy and healthy holiday season. $KAPA #HappyHolidays

A look back at a major milestone for #KairosPharma. Last year's bell ringing at the NYSE 🏛 marked an important step in $KAPA's journey as a public company and our mission to address #cancertreatment resistance.

As the new year begins, #KairosPharma reflects on key 2025 milestones, including Phase I and II data and continued pipeline progress. In 2026, #KAPA remains focused on advancing our clinical pipeline. Learn more: bit.ly/4mxVgPt $KAPA #Milestones #ProstateCancer

Lung and #prostatecancer rely on different #receptors to grow, shaping how therapies are developed. These differences shape how therapies are developed and where new innovations are needed. Learn more about $KAPA's work in #cancer: bit.ly/48wrBC #LungCancer

#ICYMI: Urology Times shared encouraging interim data from #KairosPharma’s Phase 2 trial of #ENV105 & apalutamide in #mCRPC. The combo showed a median PFS over 13 months with a well-tolerated safety profile & no dose-limiting toxicities. Read more: bit.ly/3XOwtfU $KAPA

#ProstateCancer remains one of the most commonly diagnosed cancers in men. Data from ZERO Prostate Cancer underscores the need for awareness and continued progress in #cancer research. $KAPA is advancing science-driven approaches in #oncology. Learn more: bit.ly/48wrBCM

Today kicks off the DealFlow Events Discovery Conference at the BORGATA. Excited for our Chief Scientific Officer, Neil Bhowmick, to deliver $KAPA's company presentation. #DealFlowDiscovery

#KairosPharma advances differentiated therapeutic programs rooted in strong science and globally protected intellectual property, with a focus on delivering meaningful impact for patients. Learn more: bit.ly/4pQr4kb $KAPA #ClinicalTrials  #CancerResearch

$KAPA is excited to share that Neil Bhowmick, President & CSO, will speak at The Scientist’s Emerging Therapeutic Strategies in Oncology symposium on March 17-18, 2026. Join experts as they explore the future of #cancertreatment. Register here: bit.ly/49MUdYP #Biotech

On #WorldCancerDay, #KairosPharma recognizes the global effort to advance cancer care. Through innovative approaches targeting tumor resistance, $KAPA is working to improve outcomes across cancers, including #prostatecancer and #lungcancer. #KAPA #CancerResearch

#KairosPharma is advancing innovative technologies to tackle key challenges in #cancertreatment, including drug resistance and immune modulation. Learn more about $KAPA's technologies: bit.ly/4agqw2l #Oncology

In a recent Citeline In Vivo Podcast, $KAPA's CSO, Neil Bhowmick, shared insights on upcoming milestones and the Company’s #prostatecancer and #lungcancer programs. Listen here: bit.ly/48yIsoo #KAPA #CancerResearch